ClinicalTrials.gg
RecruitingNCT06365866Updated Apr 15, 2024

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

An interventional study of "BRAXX" Esophageal Brachytherapy Applicator. and Add-on of intraluminal brachytherapy in Esophageal Neoplasms, Head and Neck Neoplasms and Gastrointestinal Neoplasms, sponsored by Taipei Veterans General Hospital, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Esophageal Neoplasms with a site in Taiwan — 17 open to participants now, 29 under way, 2 of them phase 3. Esophageal Neoplasms · Taiwan.

Planned enrollment
61st of 64
20 · median 98
Started
2024
with 6 others
No phase
18 of 79
4 open now
Primary completion
2024-12
later than 2 of 28 live
Registered
71st of 79
by date
Lead sponsor
3 of 79
Taipei Veterans General Hospital, Taiwan

Among the 79 studies in Esophageal Neoplasms with a site in Taiwan, this one is the 61st largest by planned enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2024, is one of 18 with no phase, reaches primary completion later than 2 of the 28 other live ones, and was the 71st registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 79 studies in Esophageal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Esophageal Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.

Read the detailed description

Add-on of intraluminal brachytherapy with applicator:

Brachytherapy protocol starts within 12 weeks after EBRT (This is "week 1"). High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions. GTV coverage D90 should equal 100% of prescription. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.

  • Prior to undergoing any study-specific procedure, patients must read and sign the current Ethics Committee/Institutional Review Board (IRB)-approved informed consent form. All on-study procedures are permitted within the visit window of ± 2 week. CT with contrast (no contrast if contraindicated) will be done at months 6 and 9; CT or PET/CT will be done at week 12 and month 12; and endoscopy with or without biopsy will be done at week 12, month 6, 9 and 12 for evaluation of tumor response; OPD follows up at week12, month 6, 9 and 12. A patient will be withdrawn from this study in the situation of any grade 4 toxicities. As for any adverse effects≧grade3, dose reduction, or dose delay according to the tolerability of individual patients is allowed. Grade 3 toxicity will cause the rest of the treatment (at least 1 week) until recovery to ≤grade 2 toxicity. If any patient can not tolerate a full course of brachytherapy, the total dose (EBRT+brachytherapy) can be reduced to 60Gy without violation of protocol. The management of adverse effects will follow general principles. Because tumor response is usually observed after completion of treatment, patients will not withdraw from the study because of no response. However, patients should be withdrawn from the study of (1) any grade 4 toxicity or (2) any unexpected cause of SAE that needs to discontinue radiation such as stroke, heart attack, accident, infection, bleeding...etc. Any failure observed during the post-treatment period will be documented, and patients should be withdrawn from the study, facilitating other treatment interventions.
  • During this 12-month trial, any other cancer treatment (such as target therapy) and any non-cancer treatment that can increase adverse reactions within the treatment field are prohibited, so as not to affect treatment outcome or cause a change in side effects. The general management of symptoms or other non-cancer-related treatment is allowed, as long as physicians confirm that the interpretation of treatment outcome or side effects will not be influenced.
  • The Investigator may use the data collected in this study for future research; which shall be consented by the Subject in the consent form.
03

Conditions studied

  • Esophageal Neoplasms
  • Head and Neck Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Diseases
  • Digestive System Neoplasms
  • Esophageal Diseases
  • Neoplasms by Site
  • Gastrointestinal Diseases
  • Neoplasms

Keywords

  • Brachytherapy
  • Esophageal cancer
  • External beam radiotherapy
  • Intraluminal brachytherapy
  • Survival
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 20-85 years, with performance 0-2.
  • Thoracic esophageal cancer with clinical stage I-IV and proof; patient with stage I-IV cervical esophageal cancer could be recruited in this trial according to Investigator's assessment.
  • Complete CCRT with total doses of 45-55Gy to GTV via external beam radiotherapy (EBRT).

Exclusion criteria

Exclusion Criteria:

  • According to Investigator's assessment, patients with double cancer or recurrence could be recruited in this trial if they continue to receive systemic therapy.
  • Patient with double cancer, esophageal cancer or recurrence who is scheduled for surgery treatment.
  • Involvement of tracheal mucosa or bronchial mucosa.
  • Stenosis of esophageal lumen that cannot be bypassed by the applicator after EBRT.
  • The distribution of the lesions of interest exceeds 10cm range.
  • The patient is participating in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Add-on of intraluminal brachytherapy with "BRAXX" Esophageal Brachytherapy Applicator.

    Brachytherapy protocol starts 3 weeks after EBRT (This is "week 1"). After transnasal insertion of the applicator into the esophagus, CT simulation scan(s) with a dummy source in place will be done for further planning procedures, including adjustment of the applicator and 3D treatment planning.

    Device: "BRAXX" Esophageal Brachytherapy Applicator. · Radiation: Add-on of intraluminal brachytherapy

Interventions

  • Device"BRAXX" Esophageal Brachytherapy Applicator.

    The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.

  • RadiationAdd-on of intraluminal brachytherapy

    Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.

06

What researchers measure

Primary outcomes

  1. To estimate the local control rate at primary tumor site.

    Subjects will be followed every 3 months after treatment, EGD-endoscopy (± biopsy) and PET/ CT scans will be arranged in Months 3, 6, 9, and 12 to evaluate the tumor status.

    Time frame: 12 months after completion of treatment

Secondary outcomes

  1. To estimate overall response rate.

    The overall response rate was observed within 1 year.

    Time frame: 12 months after completion of treatment

  2. To estimate distant metastasis rate.

    Subjects' distant metastasis rate was observed within 1 year.

    Time frame: 12 months after completion of treatment

  3. To estimate progression-free survival rate.

    Subjects' progression-free survival rate was observed within 1 year.

    Time frame: 12 months after completion of treatment

  4. To estimate overall survival status.

    Subjects' overall survival status was observed within 1 year.

    Time frame: 12 months after completion of treatment

  5. To estimate toxicity analysis.

    All toxicities related to the treatment in this clinical trial will be recorded using the Common Toxicity Criteria version 5.0 developed by the National Cancer Institute.

    Time frame: 12 months after completion of treatment

  6. To estimate adverse event.

    Adverse events of less severity are reported on case report forms and submitted with routine data submission. A submission of severe adverse effect (SAE) report includes every admission and ER visit of any reason within 3 months of treatment.

    Time frame: 3 months after completion of treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 10 months is below that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Apr 15, 2024
StartActual
Feb 19, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06365866
Responsible party
Pin-I Huang (Attending Physcian, Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taiwan) — Principal investigator
First posted
Apr 15, 2024
Start date
Feb 19, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 15, 2024

Study contacts

Pin-I Huang, Ph.D
Contact
pihuang@vghtpe.gov.tw
+886-2-2875-7270
Pin-I Huang, Ph.D
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion